Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04663347 : A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

One/TwoPhase One/Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Treatment | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Follicular Lymphoma

Trial Overview Read MoreRead more

This phase I/II trial is trying to understand how safe and tolerable a targeted therapy drug (epcoritamab) is when combined with standard of care treatments, including chemotherapy, steroids and other targeted therapy drugs, in people with B-cell Non-Hodgkin Lymphoma.
 

This trial is treating patients with B-cell non-Hodgkin lymphoma and Follicular lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma

Commercial Sponsor

Genmab

Summary

This is a non-randomised trial with five experimental arms. Each arm has 2 parts: Part 1 (dose escalation) and Part 2 (expansion). Within each arm, participants can only participate in one part. Experimental Arm 1 is investigating epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Arm 2 is investigating epcoritamab + rituximab and lenalidomide (R2) in people with relapsed/refractory (R/R) follicular lymphoma (FL). Experimental Arm 3 is investigating epcoritamab + rituximab and bendamustine (BR) in people with previously untreated FL. Experimental Arm 4 is investigating epcoritamab + rituximab, cisplatin, cytarabine, and dexamethasone (R-DHAX/C) in people with R/R DLBCL eligible for autologous stem cell transplant (ASCT). Experimental Arm 5 is investigating epcoritamab + gemcitabine and oxaliplatin (GemOx) in people with R/R DLBCL ineligible for ASCT due to age, performance status (PS), or comorbidity.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next